Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 1, 2017

Can-Fite begins enrolment in Phase III rheumatoid arthritis trial

Israeli biotechnology firm Can-Fite BioPharma has started patient enrolment and dosing in a Phase III clinical trial (ACRobat) of its drug candidate Piclidenoson (CF101) for the treatment of rheumatoid arthritis.

Israeli biotechnology firm Can-Fite BioPharma has started patient enrolment and dosing in a Phase III clinical trial (ACRobat) of its drug candidate Piclidenoson (CF101) for the treatment of rheumatoid arthritis.

Piclidenoson is an oral, small molecule agonist of A3 adenosine receptor

(A3AR) being developed to treat autoimmune inflammatory diseases.

In the Phase III trial, the drug candidate will be assessed as a first line treatment for the replacement of existing standard of care drug Methotrexate (MTX) for rheumatoid arthritis.

Reportedly, 50% of patients discontinue treatment with MTX due to drug intolerance, minor and major side-effects and lack of efficacy.

In previous Phase III trials with subjects who did not undergo prior systemic therapy, Piclidenoson was reported to have demonstrated favourable efficacy comparable to MTX.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
“We believe that rheumatologists are looking for a safer and more effective alternative.”

Can-Fite CEO Dr Pnina Fishman said: “We believe Piclidenoson is a potentially superior option to the standard of care, MTX, and we believe that rheumatologists are looking for a safer and more effective alternative.”

The randomised, double-blind, active and placebo-controlled ACRobat trial will investigate the long-term safety and efficacy of 1mg and 2mg twice-a-day dose of Piclidenoson in 500 participants for a period of 24 weeks at centres across Europe, Israel and Canada.

ACRobat’s primary endpoint of low disease activity following 12 weeks of treatment with Piclidenoson will be compared to once weekly dose of MTX.

Next year, the firm plans to further study Piclidenoson in another Phase III trial for treating patients suffering from moderate-to-severe psoriasis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU